Results 31 to 40 of about 39,374 (166)

Uso precoce e tardio de dopamina após isquemia miocárdica Early and late use of dopamine after myocardial ischemia

Brazilian Journal of Cardiovascular Surgery, 2004
OBJETIVO: Avaliar os efeitos na função ventricular esquerda do uso precoce e tardio de dopamina, em modelo experimental de coração isolado. MÉTODO: Foram utilizados 60 coelhos em modelo de coração isolado mantido por animal suporte.
Ademar R. Souza, Marcos A. M. Silva, Rubens R. Andrade, Reinaldo A. Oliveira, Antônio S. Martins   +4 more
doaj   +1 more source

The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson’s Disease

Cells, 2020
Levodopa (L-DOPA) treatment in Parkinson’s disease is limited by the emergence of L-DOPA-induced dyskinesia. Such dyskinesia is associated with aberrant gene regulation in neurons of the striatum, which is caused by abnormal dopamine release from ...
Feras Altwal, Connor Moon, Anthony R. West, Heinz Steiner   +3 more
doaj   +1 more source

L-Dopa and the albino riddle: content of L-Dopa in the developing retina of pigmented and albino mice. [PDF]

PLoS ONE, 2013
The absence or deficiency of melanin as in albinos, has detrimental effects on retinal development that include aberrant axonal projections from eye to brain and impaired vision. In pigmented retinal pigment epithelium (RPE), dihydroxyphenalanine (L-Dopa)
Suzanne Roffler-Tarlov, Jin Hong Liu, Elena N Naumova, Maria Margarita Bernal-Ayala, Carol A Mason   +4 more
doaj   +1 more source

The role of L-DOPA in plants [PDF]

Plant Signaling & Behavior, 2014
Since higher plants regularly release organic compounds into the environment, their decay products are often added to the soil matrix and a few have been reported as agents of plant-plant interactions. These compounds, active against higher plants, typically suppress seed germination, cause injury to root growth and other meristems, and inhibit ...
Anderson Ricardo, Soares, Rogério, Marchiosi, Rita de Cássia, Siqueira-Soares, Rogério, Barbosa de Lima, Wanderley, Dantas dos Santos, Osvaldo, Ferrarese-Filho   +5 more
openaire   +2 more sources

Hypotension Caused by L-Dopa [PDF]

BMJ, 1970
In 20 patients with idiopathic Parkinsonism maximum tolerated doses of L-dopa were found to induce a mean reduction in blood pressure (erect systolic) of 19·3 mm.Hg, without any significant change in pulse rate. This hypotension may be due to dopamine, acting on adrenergic nerve endings or on the central nervous system itself.
D B, Calne, J, Brennan, A S, Spiers, G M, Stern   +3 more
openaire   +2 more sources

Effect of Thermal Processing on Color, Phenolic Compounds, and Antioxidant Activity of Faba Bean (Vicia faba L.) Leaves and Seeds

Antioxidants, 2021
The leaves and seeds of the faba bean are good sources of L-3,4-dihydroxyphenylalanin (L-dopa), and are usually eaten with thermal cooking methods. However, little information is available on the effect of thermal treatments on their nutritional value ...
Shu-Cheng Duan, Soon-Jae Kwon, Seok-Hyun Eom   +2 more
doaj   +1 more source

Nitric oxide synthase inhibitor improves de novo and long-term L-DOPA-induced dyskinesia in hemiparkinsonian rats

Frontiers in Systems Neuroscience, 2011
Inhibitors of neuronal and endothelial nitric oxide synthase decrease l-3,4-dihidroxifenilalanine (L-DOPA)-induced dyskinesias in rodents. The mechanism of nitric oxide inhibitor action is unknown.
Fernando Eduardo Padovan-Neto, Fernando Eduardo Padovan-Neto, Marcela Bermúdez Echeverry, Marcela Bermúdez Echeverry, Silvana eChiavegatto, Elaine eDel Bel, Elaine eDel Bel   +6 more
doaj   +1 more source

L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study

Parkinson's Disease, 2015
Objectives. To characterize the pharmacokinetic profile of levodopa (L-dopa) and carbidopa after repeated doses of the effervescent tablet of melevodopa/carbidopa (V1512; Sirio) compared with standard-release L-dopa/carbidopa in patients with fluctuating
Fabrizio Stocchi, Laura Vacca, Paola Grassini, Stephen Pawsey, Holly Whale, Stefano Marconi, Margherita Torti   +6 more
doaj   +1 more source

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease

Molecules, 2017
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and less than 1% of the oral dose is ...
Monique Hoon, Jacobus P. Petzer, Francois Viljoen, Anél Petzer   +3 more
doaj   +1 more source

The Effect of Chronic Treatment with the Inhibitor of Phosphodiesterase 5 (PDE5), Sildenafil, in Combination with L-DOPA on Asymmetric Behavior and Monoamine Catabolism in the Striatum and Substantia Nigra of Unilaterally 6-OHDA-Lesioned Rats

Molecules
The use of phosphodiesterase inhibitors in the treatment of Parkinson’s disease is currently widely discussed. The study aimed to investigate the impact of acute and chronic treatment with the phosphodiesterase 5 inhibitor, sildenafil, at low and ...
Elżbieta Lorenc-Koci, Kinga Kamińska, Tomasz Lenda, Jolanta Konieczny   +3 more
doaj   +1 more source